Back to Search
Start Over
High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study.
- Source :
-
Clinical & Experimental Medicine . Feb2023, Vol. 23 Issue 1, p87-96. 10p. - Publication Year :
- 2023
-
Abstract
- The incidence of oropharyngeal cancers (OPC) is increasing in the world. Among OPC, those induced by human papillomaviruses have a better prognosis than non-HPV-associated OPC. The objective of this study was to highlight the relevance of HPV16 load, HPV16 DNA integration and HPV16-L1 serology on progression-free survival and overall survival of OPC patients. The PAPILLOPHAR cohort consists of 362 patients with oropharyngeal squamous cell carcinomas prospectively followed up for 5 years after treatment. Tumor biopsies and sera were collected at inclusion to investigate tumor HPV DNA/RNA characteristics and HPV16 L1 serology, respectively. Twenty-seven percent of tumor biopsies were HPV DNA- and RNA-positive and HPV16 represented 93% of HPV-positive cases. Among them, neither HPV16 viral load nor HPV16 DNA integration was associated with overall survival (OS) or progression-free survival (PFS). In contrast, high anti-HPV16 L1 antibody titers were significantly associated with a better OS and PFS. This study reveals that HPV16 load and integration are not relevant prognosis biomarkers in OPC patients. Clinical Relevance: High levels of HPV16 L1 antibodies may be useful to predict OPC patient outcome following treatment. ClinicalTrials.gov Identifier: NCT00918710, May 2017. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15918890
- Volume :
- 23
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Clinical & Experimental Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 161960040
- Full Text :
- https://doi.org/10.1007/s10238-022-00796-2